NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=166078&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Informatica Inc. ("Informatica Inc.") (NYSE:INFA) concerning possible violations of federal securities laws. On February 13, 2025, Informatica issued a press release announcing its fourth quarter 2024 financial results, missing revenue forecasts and

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cytokinetics, Incorporated ("Cytokinetics, Incorporated") (NASDAQ:CYTK) concerning possible violations of federal securities laws. BioPharma Dive published a report on Cytokinetics on May 2, 2025, and stated that, "The Food and Drug Administration has

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Replimune Group, Inc. (NASDAQ:REPL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=166059&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Alto Neuroscience, Inc. (NYSE:ANRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=166076&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BellRing Brands, Inc. (NYSE:BRBR) for potential violations of the federal securities laws. If you invested in BellRing, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/bellring-brands-inc-class-action-lawsuit. Why is BellRing

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Unicycive Therapeutics, Inc. (NASDAQ:UNCY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?prid=166075&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Charter Communications, Inc. (NASDAQ:CHTR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/charter-communications-inc-lawsuit-submission-form?prid=166060&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your PubMatic, Inc. (NASDAQ:PUBM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pubmatic-inc-lawsuit-submission-form?prid=166061&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / September 9, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=166062&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or